Clinical Trials on Lung Cancers

Total 96625 results

Avistone Biotechnology Co., Ltd.

Recruiting

A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) (Kannon)

Non-Small-Cell Lung Cancer

China
Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator...

Not yet recruiting

Pharmacogenomics IND EXEMPT SNP Clinical Study - Alectinib and Single Nucleotide Polymorphisms (Drugs-SNPs)

Non-small Cell Lung Cancer

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Evaluation of the Efficacy and Safety of AL2846 Capsule Combined With TQB2450 Injection Compared to Docetaxel Injection in Advanced Non-small Cell Lung Cancer Patients Who Have Failed With Immunotherapy.

Non-small Cell Lung Cancer

China
Erasmus Medical Center

Recruiting

TEIPP Immunotherapy in Patients With NSCLC (TEIPP)

Non Small Cell Lung Cancer

Netherlands
Klus Pharma Inc.
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Recruiting

A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)

Non-small Cell Lung Cancer

China
Columbia University

Not yet recruiting

Apricity CARE to Improve ICI Outcomes of Ethnic/Racial Minority NSCLC Patients

Non Small Cell Lung Cancer

United States
Fondazione Policlinico Universitario Agostino Gemelli...
Technische Universität Dresden; University of Debrecen; Koc University Hospital; Hospital de la Santa creu i Sant Pau - Barcelona and other collaborators

Not yet recruiting

Lung Cancer Multi-omics Digital Human Avatars for Integrating Precision Medicine Into Clinical Practice (LANTERN)

Non Small Cell Lung Cancer
Innate Pharma

Recruiting

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)

Non Small Cell Lung Cancer

France, United States, Greece, Hungary, Poland
Sanguine Biosciences

Recruiting

Prospective Collection of Whole Blood From Active Non-Small Cell Lung Cancer Patients for Supplemental Research

Non Small Cell Lung Cancer

United States
Peking Union Medical College Hospital
Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Recruiting

Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15) (WU-KONG15)

Non Small Cell Lung Cancer

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

Non-small Cell Lung Cancer
VA Office of Research and Development
VA Greater Los Angeles Healthcare System

Not yet recruiting

EZH2 Inhibitor, Tazemetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

United States
Hunan Cancer Hospital
Henan Cancer Hospital; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

Non Small Cell Lung Cancer

China
Peking Union Medical College Hospital

Recruiting

Adjuvant Furmonertinib in Stage IA With High Risk Factors and Stage IB Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Non-small Cell Lung Cancer

China
Novartis Pharmaceuticals

Recruiting

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

United States, Korea, Republic of, Spain, Japan, Germany, Switzerland
Instituto Portugues de Oncologia, Francisco Gentil...
AstraZeneca

Recruiting

Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy (IDEAR)

Non-small Cell Lung Cancer

Portugal
Norwegian University of Science and Technology
Karolinska University Hospital; Oslo University Hospital; University Hospital... and other collaborators

Recruiting

Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer (TRIPLEX)

Small-cell Lung Cancer

Netherlands, Norway, Sweden, Estonia, Iceland
Yonsei University

Not yet recruiting

Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)

Non Small Cell Lung Cancer

Korea, Republic of
PharmaMar

Recruiting

Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)

Relapsed Small Cell Lung Cancer

United States, Spain, Japan, Korea, Republic of, United Kingdom, Israel, France, Taiwan, Germany, Australia, Belgium, Georgia, Italy, Switzerland, Denmark, Hungary, Poland, Romania, Canada, Brazil, Bulgaria, Austria, Chile, Turkey
China Resources Sanjiu Medical & Pharmaceutical...

Not yet recruiting

Jinfukang Oral Liquid Combined With Chemotherapy for Treating Driver Gene-negative Advanced NSCLC

Non Small Cell Lung Cancer
Jiangxi Provincial Cancer Hospital
Inner Mongolia Agricultural University

Recruiting

Lactobacillus Bifidobacterium V9(Kex02)Improving the Efficacy of Carilizumab Combined With Platinum in Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer

China
Genprex, Inc.

Recruiting

Quaratusugene Ozeplasmid (Reqorsa) in Combination With Pembrolizumab in Previously Treated Non-Small Lung Cancer (Acclaim-2)

Non Small Cell Lung Cancer

United States
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC

Non Small Cell Lung Cancer

China
AstraZeneca
Parexel

Recruiting

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer (NeoCOAST-2)

Non-small Cell Lung Cancer

Hungary, United States, Italy, Belgium, Spain, France, Korea, Republic of, Taiwan, Turkey, Ireland, Portugal, Canada
Yonsei University

Not yet recruiting

Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer (SKYROCKET)

Non-small Cell Lung Cancer

Korea, Republic of
Frame Pharmaceuticals B.V.
University Medical Center Groningen; Erasmus Medical Center; The Netherlands... and other collaborators

Not yet recruiting

FRAME-001 Personalized Vaccine in NSCLC

Non Small Cell Lung Cancer

Netherlands
University Health Network, Toronto
Bristol-Myers Squibb

Recruiting

Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer (ATLAS)

Non Small Cell Lung Cancer

Canada
Beijing Chest Hospital

Not yet recruiting

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Non-small Cell Lung Cancer
NovoCure GmbH
Merck Sharp & Dohme LLC

Recruiting

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer (KEYNOTE B36)

Non-small Cell Lung Cancer

United States
Tang-Du Hospital

Recruiting

A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC

Non Small Cell Lung Cancer

China
Columbia University

Recruiting

Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab

Non Small Cell Lung Cancer

United States
Shanghai Pulmonary Hospital, Shanghai, China

Not yet recruiting

Adjuvant Toripalimab Plus Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) NSCLC (LungMate-008)

Non Small Cell Lung Cancer
University Hospital Ostrava

Recruiting

Consolidation Conventional Radiotherapy + Stereotactic Body Radiotherapy at 3 Months After First-line Chemotherapy in Stage IV Oligometastatic Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

Czechia
University Hospital, Lille

Recruiting

Prediction of Response to Treatment With Immunotherapy + Chemotherapy in Non-Small Cell Lung Cancer (PRINCE)

Non-small Cell Lung Cancer

France
University Hospital, Brest
Groupe Français de Pneumo-Cancérologie

Recruiting

PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (PERSEE)

Non-small-cell Lung Cancer

France
Sun Yat-sen University

Recruiting

Study of Radiotherapy Combined With Albumin Bound Paclitaxel and Nedaplatin for Locally Advanced NSCLC

Non-small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Chemotherapy Combined With Immunotherapy in HER 2 Insertion or Amplification Advanced NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

Non-small Cell Lung Cancer

China
Shanghai 10th People's Hospital

Recruiting

Mitochondria-targeted System Therapy Combined With Radiofrequency Ablation for Early-stage Non-small Cell Lung Cancer

Non Small Cell Lung Cancer

China
Centre Henri Becquerel

Recruiting

Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment (iTEP1)

Non Small Cell Lung Cancer

France
Hunan Province Tumor Hospital

Recruiting

Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
Sichuan University
Geneplus-Beijing Co. Ltd.

Recruiting

A Prospective Study of Constructing Immune Repertoire to Monitor the Therapeutic Effect in NSCLC Patients

Non-small Cell Lung Cancer

China
Ruijin Hospital
Shanghai Houchao Biotechnology Co., Ltd

Recruiting

Study of High Efficient Killing Cell Therapy for Advanced NSCLC (HEART)

Non Small Cell Lung Cancer

China
Erasmus Medical Center

Recruiting

Determination of Peripheral Immune Cell Activity During Treatment With Either Surgery or Radiotherapy in Patients With Early Stage NSCLC (HAMLET)

Non-small Cell Lung Cancer

Netherlands
BeiGene

Active, not recruiting

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Non Small Cell Lung Cancer

China
Roswell Park Cancer Institute

Active, not recruiting

A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States
Celgene

Terminated

Selective HDAC6 Inhibitor ACY 241 in Combination With Nivolumab in Patients With Unresectable Non Small Cell Lung Cancer

Non Small Cell Lung Cancer

United States
BeiGene

Completed

Comparison of Efficacy and Safety of Anti-PD-1 Antibody BGB-A317 Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With NSCLC

Non-small Cell Lung Cancer

China, Russian Federation, New Zealand, Lithuania, Turkey, Brazil, Bulgaria, Poland, Mexico, Slovakia
Taofeek Owonikoko
National Cancer Institute (NCI); Cardiff Oncology

Active, not recruiting

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Small Cell Lung Carcinoma | Small-cell Lung Cancer

United States

3

Subscribe